Daiichi Sankyo Co Ltd R&D Day (English, Japanese) Transcript
[Interpreted] I'm Manabe, President and CEO of Daiichi Sankyo. Thank you very much for participating in Daiichi Sankyo's R&D Day despite your very busy schedule at the end of the year.
Today, I will first explain the strengths of Daiichi Sankyo's R&D and share some top line strategic direction for the future. Following my presentation, Junichi Koga, our Global R&D Head, will explain our R&D strategies; and then Antoine Yver, our Global Oncology R&D Head, will provide an update on the status of our R&D in the Oncology area and our future plans.
First, I'd like to talk about the emphasis I place on our R&D. I believe that the strength of our R&D comes from leveraging the combined science and technology capabilities from across the organization. There are 3 sources. The first source is our in-house drug creation capabilities cultivated over the many years. Since our founding more than 100 years ago, Daiichi Sankyo has developed innovative pharmaceuticals as a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
